Development and Characterization of a Potent Tumor Necrosis Factor-Alpha-Blocking Agent

Area of Science:

• Immunology and Molecular Biology
• Biotechnology and Therapeutic Antibody Development

Background:

• Tumor necrosis factor-alpha (TNFα) is a key pro-inflammatory cytokine crucial for immune responses.
• Chronic elevation of TNFα contributes to inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease.
• Existing TNFα inhibitors offer palliative treatment, highlighting the need for novel therapeutic antibodies.

Purpose of the Study:

• To develop a novel monoclonal antibody (mAb) targeting human TNFα for therapeutic inhibition of TNFα-mediated cytotoxicity.
• To characterize the binding affinity and epitope of the developed anti-TNFα antibody.

Main Methods:

• Generation and screening of hybridoma clones producing monoclonal antibodies against human TNFα.
• Functional assays to assess antibody efficacy in protecting cells from TNFα-induced death.
• Epitope mapping using amino acid sequence analysis and bioinformatics modeling of antigen/antibody complexes.

Main Results:

• Four hybridoma clones secreted mAbs that neutralized TNFα-induced cytotoxicity; mAb C8 exhibited the highest affinity.
• The core epitope for mAb C8 binding was identified within amino acids 102-104 (glutamine, arginine, glutamic acid) of TNFα.
• mAb C8 demonstrated binding affinity comparable to the commercially available anti-TNFα antibody, infliximab.

Conclusions:

• Monoclonal antibody C8 is a potent inhibitor of human TNFα, targeting a specific epitope.
• mAb C8 represents a promising candidate for therapeutic intervention in TNFα-driven inflammatory diseases.
• The characterized epitope provides insights into TNFα-antibody interactions for future drug design.